Tech Company Financing Transactions
Ventus Therapeutics Funding Round
Ventus Therapeutics, based in Waltham, scored $60 million in funding from Versant Ventures and GV.
Transaction Overview
Company Name
Announced On
5/7/2020
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors
Versant Ventures (Lead Investor) (Jerel Davis)
Proceeds Purpose
Proceeds will be used to advance three pipeline programs and to expand the company's structural immunology platform to pursue previously intractable drug targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
100 Beaver St. 202
Waltham, MA 02453
USA
Waltham, MA 02453
USA
Phone
Website
Email Address
Overview
At Ventus, we are focused on discovering and developing novel therapeutics that target the innate immune system with the goal of addressing autoimmune diseases, inflammatory diseases, and cancer. Guided by a patient-centric ethos, our aim is to rapidly advance multiple drug candidates. Our emerging pipeline focuses on the inflammasome and nucleic acid sensing pathways.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Hao Wu
Chief Executive Officer
Marcelo Bigal
Chief Financial Officer
Zack McNealy
Founder
Richard Flavell
Founder
Judy Lieberman
Founder
Thomas Tuschl
Vice President
Michael Turner
VP - Bus. Development
Daniel Koerwer
VP - R & D
Michael Crackower
Browse more venture capital transactions:
Prev: 5/6/2020: GigaSpaces Technologies venture capital transaction
Next: 5/7/2020: LetsGetChecked venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs